DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer
Executive with Extensive Track Record in Neurology and Rare Disease Drug DevelopmentMINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointme...
Source: pharmiweb.com